c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease
Open Access
- 28 December 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 17 (12) , e1009711
Abstract
Polycystic kidney disease is an inherited degenerative disease in which the uriniferous tubules are replaced by expanding fluid-filled cysts that ultimately destroy organ function. Autosomal dominant polycystic kidney disease (ADPKD) is the most common form, afflicting approximately 1 in 1,000 people. It primarily is caused by mutations in the transmembrane proteins polycystin-1 (Pkd1) and polycystin-2 (Pkd2). The most proximal effects ofPkdmutations leading to cyst formation are not known, but pro-proliferative signaling must be involved for the tubule epithelial cells to increase in number over time. The c-Jun N-terminal kinase (JNK) pathway promotes proliferation and is activated in acute and chronic kidney diseases. Using a mouse model of cystic kidney disease caused byPkd2loss, we observe JNK activation in cystic kidneys and observe increased nuclear phospho c-Jun in cystic epithelium. Genetic removal ofJnk1andJnk2suppresses the nuclear accumulation of phospho c-Jun, reduces proliferation and reduces the severity of cystic disease. WhileJnk1andJnk2are thought to have largely overlapping functions, we find thatJnk1loss is nearly as effective as the double loss ofJnk1andJnk2. Jnk pathway inhibitors are in development for neurodegeneration, cancer, and fibrotic diseases. Our work suggests that the JNK pathway should be explored as a therapeutic target for ADPKD.Keywords
All Related Versions
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (DK103632)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK107220)
This publication has 83 references indexed in Scilit:
- Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney diseaseBMC Nephrology, 2012
- TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathwayGenes & Development, 2011
- Pkd1 and Pkd2 Are Required for Normal Placental DevelopmentPLOS ONE, 2010
- Polycystin-1 Protein Level Determines Activity of the Gα12/JNK Apoptosis PathwayJournal of Biological Chemistry, 2010
- c-Jun NH2-Terminal Kinase Is Crucially Involved in Renal Tubulo-Interstitial InflammationThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Pkd2 Dosage Influences Cellular Repair Responses following Ischemia-Reperfusion InjuryThe American Journal of Pathology, 2009
- Cre recombinase activity specific to postnatal, premeiotic male germ cells in transgenic miceGenesis, 2008
- A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1Nature Medicine, 2007
- Suppression of p53-dependent senescence by the JNK signal transduction pathwayProceedings of the National Academy of Sciences, 2007
- Restoration of p53 function leads to tumour regression in vivoNature, 2007